179 related articles for article (PubMed ID: 37936709)
21. Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.
Maurya R; Shamim U; Mishra P; Swaminathan A; Raina A; Tarai B; Budhiraja S; Pandey R
Microbiol Spectr; 2023 Jun; 11(3):e0429222. PubMed ID: 37022180
[TBL] [Abstract][Full Text] [Related]
22. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
23. Sex-based clinical and immunological differences in COVID-19.
Huang B; Cai Y; Li N; Li K; Wang Z; Li L; Wu L; Zhu M; Li J; Wang Z; Wu M; Li W; Wu W; Zhang L; Xia X; Wang S; Chen H; Wang Q
BMC Infect Dis; 2021 Jul; 21(1):647. PubMed ID: 34225644
[TBL] [Abstract][Full Text] [Related]
24. [Clinical features of children with coronavirus disease 2019 Delta variant infection after vaccination with inactivated SARS-CoV-2 vaccine].
Su H; Zhang X; Duan FY; Ren XQ; Yan YB; Ding Y
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):742-747. PubMed ID: 35894187
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the combination of BRII-196/BRII-198 in the treatment of COVID-19 vaccine breakthrough infections.
Guo XL; Wang K; Jin J; Dai LL
Am J Transl Res; 2024; 16(3):916-924. PubMed ID: 38586111
[TBL] [Abstract][Full Text] [Related]
26. [Influence of SARS-CoV-2 vaccination on the epidemiological and clinical characteristics of imported COVID-19 cases in Chengdu].
Yue Y; Liang X; Mao Y; Hu M; Han DL; Su LY; Chen H; Fan SF; Zhang XC; Yang F; Yuan QW; Liu Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Aug; 42(8):1365-1370. PubMed ID: 34814555
[No Abstract] [Full Text] [Related]
27. High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients.
Liu D; Yuan X; Gao F; Zhao B; Ding L; Huan M; Liu C; Jiang L
Front Immunol; 2022; 13():899930. PubMed ID: 35865540
[TBL] [Abstract][Full Text] [Related]
28. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant].
Feng Q; Wang Z; Yu H; Shi L; Xu L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):459-464. PubMed ID: 35728844
[TBL] [Abstract][Full Text] [Related]
30. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China.
Xu B; Fan CY; Wang AL; Zou YL; Yu YH; He C; Xia WG; Zhang JX; Miao Q
J Infect; 2020 Jul; 81(1):e51-e60. PubMed ID: 32315725
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
32. Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection.
Duro M; Almeida C; Duro I; Sarmento A
Ir J Med Sci; 2023 Apr; 192(2):731-739. PubMed ID: 35676470
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia.
Karachaliou M; Moncunill G; Espinosa A; Castaño-Vinyals G; Rubio R; Vidal M; Jiménez A; Prados E; Carreras A; Cortés B; Blay N; Bañuls M; Pleguezuelos V; Melero NR; Serra P; Parras D; Izquierdo L; Santamaría P; Carolis C; Papantoniou K; Goldberg X; Aguilar R; Garcia-Aymerich J; de Cid R; Kogevinas M; Dobaño C
BMC Med; 2022 Sep; 20(1):347. PubMed ID: 36109713
[TBL] [Abstract][Full Text] [Related]
34. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of clinical value of Xuebijing combined with human immunoglobulin in severe and critically ill patients with coronavirus disease 2019].
Chen L; Zhang A; Li Q; Cui Y; Yuan G
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Apr; 33(4):399-404. PubMed ID: 34053480
[TBL] [Abstract][Full Text] [Related]
36. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
[TBL] [Abstract][Full Text] [Related]
37. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
38. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
39. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.
Han M; Xu M; Zhang Y; Liu Z; Li S; He T; Li J; Gao Y; Liu W; Li T; Chen Z; Huang X; Cheng G; Wang J; Dittmer U; Witzke O; Zou G; Li X; Lu M; Zhang Z
Med Microbiol Immunol; 2020 Dec; 209(6):657-668. PubMed ID: 32860073
[TBL] [Abstract][Full Text] [Related]
40. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
